Legal & Disputes
Halozyme Vows Immediate Infringement Suit Against Merck After German Court Overturns Keytruda SC Ban
By News Desk ·
Key takeaways
- The Munich Higher Regional Court overturned a December 2025 preliminary injunction that had ordered Merck to refrain from distributing Keytruda SC in Germany.
- Halozyme Chief Legal Officer Mark Snyder said the company will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief.
- In October 2026, a Dutch patent court prohibited Merck's European Marketing Approval holder from infringing in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.
Halozyme Therapeutics said the German Higher Regional Court overturned a preliminary injunction that had ordered Merck to stop distributing and offering Keytruda SC in Germany. The San Diego company announced the ruling on November 19, 2026, according to PR Newswire. Halozyme develops drug delivery technologies, including ENHANZE, that enable subcutaneous administration of injectable therapeutics, and licenses them to pharmaceutical partners.
Halozyme's Response To The Munich Ruling
The overturned injunction was issued in December 2025. Halozyme said it disagrees with the Higher Regional Court's decision and will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief. "We are disappointed that the Higher Regional Court overturned the preliminary injunction halting the launch of Keytruda SC in Germany," said Mark Snyder, Chief Legal Officer of Halozyme. "We disagree with the decision and will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief, which is not precluded by today's decision." The patents at issue arise from Halozyme's research into nearly 7,000 modifications to human hyaluronidases, which provide a mechanism for rapid subcutaneous administration of therapeutic drugs. Halozyme said the MDASE patents are not part of its ENHANZE licensing program and are distinct from its ENHANZE patents, so the outcome of its global enforcement against Merck will not affect ENHANZE, any licensee's ability to use it, or the revenues Halozyme receives from ENHANZE licensees.
A Dutch Court's October Ruling
Separately, Halozyme said a Dutch patent court in October 2026 prohibited Merck's European Marketing Approval holder from infringing in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The prohibition covers manufacturing or causing to be manufactured, offering, putting on the market or using Keytruda SC in those countries, or importing it or holding it in stock for that purpose.
Halozyme's Licensing Business
According to akta.pro company records, Halozyme reported full-year 2025 revenue of $1.4 billion, representing 38% year-over-year growth, and royalty revenue of $868 million for the year, a 52% increase over 2024. The same records show Q1 2026 revenue of $376.7 million, a 42% year-over-year increase. Halozyme's ENHANZE technology is licensed to partners including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK and Incyte.
Earlier European Patent Ruling
In October 2026, Investors reported that Halozyme won a European patent ruling against Merck's Keytruda Qlex, potentially adding royalties, and that Halozyme reported Q2 sales and adjusted earnings up 48% with cash-flow positive status. In September 2026, Halozyme announced a proposed offering of $1.05 billion in convertible senior notes due 2033, with a 13-day option to purchase up to $150 million more, PR Newswire reported.
What Comes Next In Germany
Halozyme said it will immediately file the infringement lawsuit against Merck in Germany seeking permanent relief.